<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lenalidomide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lenalidomide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lenalidomide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11554" href="/d/html/11554.html" rel="external">see "Lenalidomide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709009"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not use lenalidomide during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe, life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting lenalidomide treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after lenalidomide treatment. To avoid embryo-fetal exposure to lenalidomide, it is only available under a restricted distribution program called Lenalidomide REMS program.</p>
<p style="text-indent:-2em;margin-left:2em;">Information about the Lenalidomide REMS program is available at http://www.lenalidomiderems.com or by calling the REMS Call Center at 1-888-423-5436.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with deletion 5q myelodysplastic syndromes had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for deletion 5q myelodysplastic syndromes should have their complete blood cell counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Venous and arterial thromboembolism:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with lenalidomide and dexamethasone therapy. Monitor for and advise patients about the signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the patient's underlying risks.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2407571"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Revlimid</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868749"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Lenalidomide;</li>
<li>JAMP-Lenalidomide;</li>
<li>NAT-Lenalidomide;</li>
<li>REDDY-Lenalidomide;</li>
<li>Revlimid;</li>
<li>SANDOZ Lenalidomide;</li>
<li>TARO-Lenalidomide</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2407576"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiogenesis Inhibitor;</li>
<li>
                        Antineoplastic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F2407611"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Thromboprophylaxis is recommended when used in combination with chemotherapy and/or dexamethasone for the treatment of multiple myeloma and may be offered to other high-risk patients when clinically appropriate; thromboprophylaxis regimen should be based on assessment of patient- and disease-specific risk factors as well as concomitant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31381464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31381464'])">Ref</a></span>). Institute appropriate management if at risk for tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00a86d2d-023b-498c-8137-3c37a93fa6a0">Chronic lymphocytic leukemia, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia, relapsed or refractory (off-label use):</b>
<b>Oral:</b> 10 mg once daily beginning on day 9 of cycle 1; administer continuously in combination with cyclic rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23270003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23270003'])">Ref</a></span>). Refer to protocol for dosage adjustment details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48925eaf-0a5b-4db7-8ad8-85a7a9637b97">Diffuse large B-cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, relapsed or refractory (off-label use):</b>
<b>Oral:</b> 25 mg once daily on days 1 to 21 of a 28-day treatment (as a single agent) cycle for up to 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18606983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18606983'])">Ref</a></span>) <b>or</b> 25 mg once daily on days 1 to 21 of a 28-day treatment cycle (in combination with tafasitamab) for up to 12 cycles, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511983'])">Ref</a></span>). Refer to protocols for dosage adjustment details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e645dbd-34e1-40c4-83a5-fcaf36d78511">Follicular lymphoma, previously treated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Follicular lymphoma, previously treated:</b>
<b>Oral:</b> 20 mg once daily on days 1 to 21 of a 28-day treatment cycle (in combination with rituximab) for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30897038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30897038'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f8e5c9a-9dab-4617-9624-ebd447859655">Mantle cell lymphoma, relapsed or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma, relapsed or progressive:</b>
<b>Oral:</b> 25 mg once daily on days 1 to 21 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24002500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24002500'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f31e952e-8cfb-422d-b4c0-e2506ebb01bc">Marginal zone lymphoma, previously treated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marginal zone lymphoma, previously treated:</b>
<b>Oral:</b> 20 mg once daily on days 1 to 21 of a 28-day treatment cycle (in combination with rituximab) for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30897038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30897038'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (labeled dose):</b>
<b>Oral:</b> 25 mg once daily on days 1 to 21 of a 28-day treatment cycle (in combination with dexamethasone [consider a reduced dexamethasone dose in patients &gt;75 years of age]). In patients not eligible for autologous hematopoietic cell transplantation, continue until disease progression or unacceptable toxicity; in transplant eligible patients, hematopoietic cell mobilization should occur within 4 cycles of a lenalidomide-containing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="803bf39b-990a-4158-995f-5bf6163854af">Multiple myeloma, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, newly diagnosed (off-label combinations): Note:</b> Refer to protocols for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:2em;">VRd (or RVd) regimen: <b>Oral</b>: 25 mg once daily on days 1 to 14 of a 21-day cycle (in combination with bortezomib and dexamethasone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422823','lexi-content-ref-20385792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422823','lexi-content-ref-20385792'])">Ref</a></span>) <b>or</b> 25 mg once daily on days 1 to 14 of a 21-day cycle (in combination with bortezomib and dexamethasone) for 8 cycles, followed by 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with dexamethasone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28017406','lexi-content-ref-32393732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28017406','lexi-content-ref-32393732'])">Ref</a></span>) <b>or </b>25 mg once daily on days 1 to 14 of a 21-day cycle (in combination with bortezomib and dexamethasone) for 3 cycles, followed by conditioning/transplant, followed (2 months after hematologic recovery in patients without progression) by 25 mg once daily (or last tolerated induction dose) on days 1 to 14 of a 21-day cycle (in combination with bortezomib and dexamethasone) for 2 cycles, followed by lenalidomide 10 mg once daily (escalated to 15 mg once daily after 3 months as tolerated) for 1 year as maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25024076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25024076'])">Ref</a></span>) <b>or </b>25 mg on days 1 to 21 of a 28-day treatment cycle (in combination with bortezomib and dexamethasone) for 6 induction cycles (with mobilization after the third induction cycle), followed by conditioning/transplant, followed by 2 additional VRd consolidation cycles 3 months after transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31484647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31484647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">VRd-lite regimen: <b>Oral</b>: 15 mg once daily on days 1 to 21 of a 35-day treatment cycle (in combination with bortezomib and dexamethasone) for 9 induction cycles, followed by 15 mg once daily (or last tolerated dose from cycle 9) on days 1 to 21 of a 28-day treatment cycle (in combination with bortezomib) for 6 consolidation cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29740809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29740809'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Daratumumab-containing regimens: <b>Oral</b>: 25 mg once daily on days 1 to 14 of a 21-day cycle (in combination with daratumumab, bortezomib, and dexamethasone; DVRd regimen) for 4 induction cycles and 2 post transplant consolidation cycles, followed by lenalidomide 10 mg once daily (escalated to 15 mg once daily after 3 months as tolerated) as maintenance therapy until disease progression or up to 2 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32325490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32325490'])">Ref</a></span>) <b>or</b> 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with daratumumab and dexamethasone; DRd regimen) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31141632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31141632'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IRd regimen: <b>Oral</b>: 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with ixazomib and dexamethasone) for 18 cycles (or until disease progression or unacceptable toxicity, whichever occurs first), followed by 10 mg once daily on days 1 to 21 of a 28-day cycle (in combination with ixazomib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33763699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33763699'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">KRd regimen: <b>Oral</b>: 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with carfilzomib and dexamethasone) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22665938','lexi-content-ref-30477009','lexi-content-ref-26181891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22665938','lexi-content-ref-30477009','lexi-content-ref-26181891'])">Ref</a></span>), followed by maintenance lenalidomide 10 mg once daily on days 1 to 21 of a 28-day cycle for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30477009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30477009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Rd regimen: <b>Oral</b>: 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with dexamethasone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25184863','lexi-content-ref-29150421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25184863','lexi-content-ref-29150421'])">Ref</a></span>) <b>or</b> 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with dexamethasone) for 4 cycles (followed by consolidation/transplant) or until disease progression or unacceptable toxicity (transplant ineligible) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19853510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19853510'])">Ref</a></span>) <b>or</b> 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with dexamethasone) for 9 induction cycles, followed by maintenance therapy of 10 mg once daily on days 1 to 21 of a 28-day cycle (lenalidomide monotherapy) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33739404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33739404'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="369c7a28-48b5-4212-bc00-5b8b12a6c76a">Multiple myeloma, maintenance therapy following autologous hematopoietic cell transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, maintenance therapy following autologous </b>
<b>hematopoietic cell transplant:</b>
<b>Oral:</b> 10 mg once daily (begin after adequate hematologic recovery [ANC ≥1,000/mm<sup>3</sup>; platelets ≥75,000/mm<sup>3</sup>]); after 3 months (if tolerated and in the absence of hematologic toxicity), increase dose to 15 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22571202','lexi-content-ref-22571201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22571202','lexi-content-ref-22571201'])">Ref</a></span>). A minimum of 2 years of lenalidomide maintenance therapy is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30932732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30932732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing</i>: 10 mg once daily on days 1 to 21 of a 28-day treatment cycle; continue until relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20048187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20048187'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac522d92-c8b2-419c-959b-57ffc7ab0312">Multiple myeloma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, relapsed or refractory (off-label combinations):</b>
<b>Note:</b> Refer to protocols for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:2em;">DRd regimen: <b>Oral</b>: 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with daratumumab and dexamethasone) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27705267','lexi-content-ref-36599114']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27705267','lexi-content-ref-36599114'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">ERd regimen: Oral: 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with elotuzumab and dexamethasone) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32887873','lexi-content-ref-26035255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32887873','lexi-content-ref-26035255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">KRd regimen: <b>Oral</b>: 25 mg once daily on days 1 to 21 of a 28-day cycle (in combination with carfilzomib and dexamethasone) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29341834','lexi-content-ref-25482145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29341834','lexi-content-ref-25482145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">VRd (or RVd) regimen: <b>Oral</b>: 15 mg once daily on days 1 to 14 of a 21-day treatment cycle for up to 8 cycles (in combination with bortezomib and dexamethasone), followed by maintenance therapy (if response or stable disease) of 15 mg once daily (or last tolerated dose in cycle 8) on days 1 to 14 of a 21-day treatment cycle (in combination with bortezomib and dexamethasone) until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24429336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24429336'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14d0d00-8706-4014-bd26-ba5ffdcc5809">Myelodysplastic syndromes, International Prognostic Scoring System low-risk or intermediate-1-risk, with deletion 5q</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic syndromes, International Prognostic Scoring System low-risk or intermediate-1-risk, with deletion 5q:</b>
<b>Oral:</b> 10 mg once daily, continue until disease progression or unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17021321','lexi-content-ref-24150217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17021321','lexi-content-ref-24150217'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-</i>
<i>label dosing:</i>
<b>Oral</b>: 10 mg once daily on days 1 to 21 of a 28-day treatment cycle <b>or</b> 5 mg once daily on days 1 to 28 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21753188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21753188'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fe5ea39-fe0b-4aa9-b3fd-088ff5cc4b1b">Myelodysplastic syndromes, International Prognostic Scoring System low-risk or intermediate-1-risk, without deletion 5q</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic syndromes, International Prognostic Scoring System low-risk or intermediate-1-risk, without deletion 5q (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent therapy:</i>
<b>Oral:</b> 10 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17893227','lexi-content-ref-27354480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17893227','lexi-content-ref-27354480'])">Ref</a></span>). Refer to protocols for dosage adjustment details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy: </i>
<b>Oral: </b>10 mg once daily on days 1 to 21 of a 28-day treatment cycle (in combination with epoetin alfa); if major erythroid response achieved following 4 cycles of treatment, continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33439748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33439748'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76dc2bd2-19ec-4170-896d-23921e6c3918">Smoldering multiple myeloma, high risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Smoldering multiple myeloma, high risk (off-label use): Oral:</b> 25 mg once daily on days 1 to 21 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity for up to 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31652094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31652094'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="777cc4cd-95d4-48e8-a0b1-f973f5588194">Systemic light chain amyloidosis, previously treated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic light chain amyloidosis, previously treated (off-label use):</b>
<b>Oral:</b> 15 mg once daily on days 1 to 21 of a 28-day cycle (in combination with dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17008538','lexi-content-ref-16960148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17008538','lexi-content-ref-16960148'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990463"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Lenalidomide Dose Adjustments for Altered Kidney Function<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>CrCl</b></p></th>
<th align="left">
<p style="text-indent:0em;">If the usual dose is <i>25 mg once daily </i>
<b>(eg, mantle cell lymphoma, multiple myeloma [combination therapy with dexamethasone]<sup>b</sup>)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>If the usual dose is <i>20 mg once daily </i>(eg, follicular lymphoma, marginal zone lymphoma)</b></p></th>
<th align="left">
<p style="text-indent:0em;">If the usual dose is <i>15 mg once daily </i>(eg, systemic light chain amyloidosis<sup>c</sup>) (no formal published recommendation; suggestions expert opinion only)</p></th>
<th align="left">
<p style="text-indent:0em;">
<b>If the usual dose is <i>10 mg once daily </i>(eg, myelodysplastic syndrome, multiple myeloma [maintenance treatment after autologous stem cell transplant])</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Maintain appropriate number of treatment days per cycle based on indication and/or protocol.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Patients with multiple myeloma and decreased CrCl may experience an improvement in kidney function (often during the first cycle of therapy) when treatment with lenalidomide is initiated; frequent CrCl measurement and subsequent dose adjustment should be considered (Chen 2020).</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Monitor kidney function closely, as acute kidney injury (usually occurring within the first 8 weeks of lenalidomide therapy) occurred in ~66% of patients in one report (Specter 2010).</p>
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>It may be preferable to use full doses down to a CrCl of 50 mL/minute, as underdosing has been suggested (Chen 2020), and other multiple myeloma studies have successfully used full dose lenalidomide in patients with CrCl ≥50 mL/minute (Bridoux 2016; Dimopoulos 2010; Dimopoulos 2016; Mikhael 2018).</p>
<p style="text-indent:0em;text-align:left;">
<sup>e</sup> Approximately 30% removed during a 4-hour hemodialysis session (Chen 2007; manufacturer's labeling).</p>
<p style="text-indent:0em;text-align:left;">
<sup>f</sup> Dimopoulos 2016b.</p>
<p style="text-indent:0em;text-align:left;">
<sup>g</sup> Based on expert opinion.</p>
<p style="text-indent:0em;text-align:left;">
<sup>h</sup> Chen 2007.</p>
<p style="text-indent:0em;text-align:left;">
<sup>i</sup> Lichtman 2014.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>CrCl &gt;60 mL/minute</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>CrCl 30 to 60 mL/minute</b></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 10 mg once daily; if treating multiple myeloma, may increase to 15 mg once daily after 2 cycles if tolerating treatment.<sup>d</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 10 mg once daily; if treating follicular lymphoma or marginal zone lymphoma may increase to 15 mg once daily after 2 cycles if tolerating treatment.</p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 10 mg once daily; further individualize based on tolerance and response.<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily; further individualize dose based on tolerance and response.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>CrCl 15 to &lt;30 mL/minute</b></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 15 mg every <b>other</b> day; if treating multiple myeloma, may increase dose to 10 mg once daily if tolerating treatment.<sup>f</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily.</p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily; further individualize based on tolerance and response.<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 2.5 mg once daily; further individualize dose based on tolerance and response.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>CrCl &lt;15 mL/minute</b></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily.</p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily.</p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily; further individualize dose based on tolerance and response.<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 2.5 mg once daily; further individualize dose based on tolerance and response.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Hemodialysis, intermittent (thrice weekly)<sup>e</sup></b></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily; when scheduled dose falls on a dialysis day administer after dialysis</p>
<p style="text-indent:0em;">
<b>or</b></p>
<p style="text-indent:0em;">
<b>Initial:</b> 15 mg 3 times weekly after dialysis on dialysis days.<sup>h</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily; when scheduled dose falls on a dialysis day, administer after dialysis.</p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily; when scheduled dose falls on a dialysis day, administer after dialysis; further individualize dose based on tolerance and response.<sup>g</sup></p>
<p style="text-indent:0em;">
<b>or</b></p>
<p style="text-indent:0em;">
<b>Initial:</b> 10 mg 3 times weekly after dialysis on dialysis days<sup>i</sup>; further individualize dose based on tolerance and response.<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 2.5 mg once daily; when scheduled dose falls on a dialysis day administer after dialysis; further individualize dose based on tolerance and response.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Peritoneal dialysis</b></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily (no data).<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily (no data).<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 5 mg once daily (no data)<sup>g</sup>; further individualize dose based on tolerance and response.<sup>g</sup></p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Initial:</b> 2.5 mg once daily (no data)<sup>g</sup>; further individualize dose based on tolerance and response.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neutropenia, thrombocytopenia) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> There are no data available to guide specific dosing recommendations. However, lenalidomide is likely removed by CRRT, therefore, dosing as for patients with CrCl 15 to &lt;30 mL/minute is suggested with close monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neutropenia, thrombocytopenia) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">PIRRT days: There are no data available to guide specific dosing recommendations. However, lenalidomide is likely removed by PIRRT, therefore, dosing as for patients with CrCl 15 to &lt;30 mL/minute is suggested with close monitoring; administer dose after PIRRT session has ended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-PIRRT days: Dose as for CrCl &lt;15 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987697"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to 1.5 times ULN or any AST &gt; ULN): There are no dosage adjustments provided in the manufacturer's labeling; however, lenalidomide disposition is not influenced by mild impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i> Interrupt lenalidomide for abnormal hepatic function tests; may consider resuming treatment at a lower dose upon return to baseline.</p></div>
<div class="block dot drugH1Div" id="F2407614"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Other concomitant anticancer therapies may also require dosage modification.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Hematologic toxicities: Note:</b> Hematologic toxicity may require the use of blood product support and/or growth factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Follicular lymphoma and marginal zone lymphoma:</i></b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Lenalidomide</b>
<b> Recommended Dosage Modifications for Hematologic Adverse Reactions in Follicular Lymphoma and Marginal Zone Lymphoma</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Lenalidomide</b>
<b> dosage modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> for ≥7 days; <b>or</b></p>
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> associated with fever (≥38.5°C [101°F]);<b> or</b></p>
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide per dosing recommendations below when ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>If starting dose was 20 mg daily</i>: Resume lenalidomide at 5 mg less than the previous dose; do not dose below 5 mg daily.</p>
<p style="text-indent:0em;text-align:left;">
<i>If starting dose was 10 mg daily</i>: Resume lenalidomide at 5 mg less than the previous dose; do not dose below 2.5 mg daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide per dosing recommendations below when platelets ≥50,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>If starting dose was 20 mg daily</i>: Resume lenalidomide at 5 mg less than the previous dose; do not dose below 5 mg daily.</p>
<p style="text-indent:0em;text-align:left;">
<i>If starting dose was 10 mg daily</i>: Resume lenalidomide at 5 mg less than the previous dose; do not dose below 2.5 mg daily.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Mantle cell lymphoma: </i></b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Lenalidomide Recommended Dosage Modifications for Hematologic Adverse Reactions in Mantle Cell Lymphoma</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Lenalidomide dosage modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> for ≥7 days; <b>or</b></p>
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> associated with fever (≥38.5°C [101°F]);<b> or</b></p>
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide when ANC ≥1,000/mm<sup>3</sup> at 5 mg less than the previous dose. Do not dose below 5 mg daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide when platelets ≥50,000/mm<sup>3</sup> at 5 mg less than the previous dose. Do not dose below 5 mg daily.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Multiple myeloma, combination therapy with dexamethasone: </i></b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Lenalidomide Recommended Dosage Modifications for Hematologic Adverse Reactions in Multiple Myeloma (Combination Therapy with Dexamethasone) </b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Lenalidomide dosage modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide per dosing recommendations below when ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>ANC ≥1,000/mm<sup>3</sup>; neutropenia is only toxicity</i>: Resume lenalidomide at 25 mg daily or initial starting dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>ANC ≥1,000/mm<sup>3</sup>; other toxicity present: </i>Resume lenalidomide at the next lower dose; do not dose below 2.5 mg daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> (subsequent occurrences)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at the next lower dose when ANC ≥1,000/mm<sup>3</sup>. Do not dose below 2.5 mg daily.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;30,000/mm<sup>3</sup> (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide at the next lower dose when platelets ≥30,000/mm<sup>3</sup>. Do not dose below 2.5 mg daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;30,000/mm<sup>3</sup> (subsequent occurrences)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at the next lower dose when platelets ≥30,000/mm<sup>3</sup>. Do not dose below 2.5 mg daily.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Multiple myeloma, maintenance following autologous cell transplant:</i></b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Lenalidomide Recommended Dosage Modifications for Hematologic Adverse Reactions in </b>
<b>Multiple Myeloma (Maintenance Therapy Following Autologous Transplant)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Lenalidomide dosage modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide at the next lower dose with continuous dosing on days 1 to 28 of a 28-day cycle when ANC ≥500/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> (subsequent occurrence at 5 mg daily [continuous] dose)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily on days 1 to 21 of a 28-day cycle when ANC ≥500/mm<sup>3</sup>. Do not dose below 5 mg daily on days 1 to 21 of a 28-day cycle.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;30,000/mm<sup>3</sup> (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide and check CBC weekly; resume lenalidomide at the next lower dose with continuous dosing on days 1 to 28 of a 28-day cycle when platelets ≥30,000/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;30,000/mm<sup>3</sup> (subsequent occurrence at 5 mg daily [continuous] dose)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily on days 1 to 21 of a 28-day cycle when platelets ≥30,000/mm<sup>3</sup>. Do not dose below 5 mg daily on days 1 to 21 of a 28-day cycle.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Myelodysplastic syndromes (with deletion 5q)</i>:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Lenalidomide Recommended Dosage Modifications for Hematologic Adverse Reactions in Myelodysplastic Syndromes (w</b>ith Deletion 5q)</caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><tbody valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>
<i>Hematologic toxicity developing WITHIN 4 weeks of starting treatment at 10 mg daily</i></b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Lenalidomide dosage modification</b></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;750/mm<sup>3</sup> (baseline ANC ≥1,000/mm<sup>3</sup>)</p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily when ANC ≥1,000/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> (baseline ANC &lt;1,000/mm<sup>3</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily when ANC ≥500/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup> (baseline platelets ≥100,000/mm<sup>3</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily when platelets ≥50,000/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50% of baseline (baseline platelets &lt;100,000/mm<sup>3</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide.</p>
<p style="text-indent:0em;text-align:left;">
<i>Baseline platelets ≥60,000/mm<sup>3</sup></i>: Resume lenalidomide at 5 mg daily when platelets ≥50,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>Baseline platelets &lt;60,000/mm<sup>3</sup></i>: Resume lenalidomide at 5 mg daily when platelets ≥30,000/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>
<i>Hematologic toxicity developing AFTER 4 weeks of starting treatment at 10 mg daily</i></b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Lenalidomide dosage modification</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> for ≥7 days; <b>or</b></p>
<p style="text-indent:0em;text-align:left;">
<b></b></p>
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> associated with fever (≥38.5°C [101°F])</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily when ANC ≥500/mm<sup>3</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;30,000/mm<sup>3</sup>;<b> or</b></p>
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup> with platelet transfusions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 5 mg daily when platelets ≥30,000/mm<sup>3 </sup>(without hemostatic failure).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>
<i>Hematologic toxicity developing on treatment at 5 mg daily</i></b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Lenalidomide dosage modification</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> for ≥7 days; <b>or</b></p>
<p style="text-indent:0em;text-align:left;">
<b></b></p>
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup> associated with fever (≥38.5°C [101°F])</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 2.5 mg daily when ANC ≥500/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;30,000/mm<sup>3</sup>;<b> or</b></p>
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup> with platelet transfusions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume lenalidomide at 2.5 mg daily when platelets ≥30,000/mm<sup>3 </sup>(without hemostatic failure).</p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonhematologic toxicities (all indications):</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Lenalidomide Recommended Dosage Modifications for Nonhematologic Adverse Reactions (All Indications)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Lenalidomide dosage modification</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> NSAIDs = nonsteroidal anti-inflammatory drugs, DRESS = drug reaction with eosinophilia and systemic symptoms.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Skin rash (grade 2 or 3)</p>
<p style="text-indent:0em;text-align:left;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Consider interruption or discontinuation of lenalidomide treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Skin rash (grade 4), exfoliative or bullous rash, severe cutaneous reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS<sup>a</sup> or other severe dermatologic reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue lenalidomide.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypersensitivity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Angioedema or anaphylaxis</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue lenalidomide.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thromboembolism</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Signs/symptoms of thromboembolism present (eg, shortness of breath, chest pain, arm/leg swelling)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Instruct patient to seek prompt medical attention.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Tumor flare reaction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1 or 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Continue therapy at provider's discretion; may consider symptom management with corticosteroids, NSAIDs<sup>a</sup>, and/or narcotic analgesic therapy.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume when tumor flare reaction resolved to ≤ grade 1; consider symptom management with corticosteroids, NSAIDs<sup>a</sup>, and/or narcotic analgesic therapy.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Other nonhematologic adverse effects</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold lenalidomide; resume at provider's discretion at the next lower dose when toxicity resolved to ≤ grade 2.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F2407612"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Due to the potential for decreased renal function in the elderly, select dose carefully and closely monitor renal function.</p></div>
<div class="block arsc drugH1Div" id="F57258242"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hematologic toxicity and infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide may cause significant <b>neutropenia </b>and <b>thrombocytopenia</b>. Eighty percent of patients with deletion 5q myelodysplastic syndromes (MDS) had to have initial dose delay/reduction and 34% of patients had to have a second dose delay/reduction during the major study. Grade 3 or 4 hematologic toxicity occurred in 80% of patients enrolled in the study. Rates and severity of hematologic toxicity may vary by indication and dosing schedule (lowest rates with lymphoma and highest with MDS, with myeloma rates in between). Median time to documented recovery of grade 3 or 4 neutropenia was 17 days and grade 3 or 4 thrombocytopenia was 22 days. Lenalidomide is known to increase risk of fatal <b>infections </b>due to neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28423741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28423741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; however, lenalidomide has multiple immunomodulatory affects that lead to decreased cell proliferation, including loss of PU.1, a key transcription factor involved in granulopoiesis, which leads to transient arrest of neutrophil maturation and subsequent neutropenia. Other mechanisms include modulation and downregulation of inflammatory cytokines, modulation of B-, T-, and NK-cells, as well as effects on the bone marrow microenvironment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26195701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26195701'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; median time to onset of grade 3 or 4 neutropenia was 42 days and grade 3 or 4 thrombocytopenia was 28 days. Data suggest incidence of infection is highest in initial months of drug treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28423741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28423741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• MDS deletion 5q versus other indications</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other myelosuppressive therapies</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Multiple myeloma disease-related complications that increase the risk of infection (eg, fractures, neutropenia, neurodegenerative disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28423741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28423741'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide may cause <b>abnormal hepatic function tests </b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17984315','lexi-content-ref-22993370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17984315','lexi-content-ref-22993370'])">Ref</a></span>). Rarely, <b>hepatic failure</b> (including fatal) has been reported in patients treated with combination lenalidomide and dexamethasone therapy. The pattern of liver injury may have cholestatic, hepatocellular, or mixed characteristics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993370'])">Ref</a></span>). Discontinuation of therapy has resulted in normalization of liver function tests in ~2 to 3 weeks (range: 8 to 30 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17984315','lexi-content-ref-22993370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17984315','lexi-content-ref-22993370'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; may have direct hepatotoxic effects. Proposed mechanisms also include changes in vascular inflow or outflow, possibly related to thrombotic effects of lenalidomide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993370'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; 7 to 10 days after initiation have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17984315','lexi-content-ref-22993370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17984315','lexi-content-ref-22993370'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevations in liver enzymes</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent hepatotoxic medications</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17984315','lexi-content-ref-22993370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17984315','lexi-content-ref-22993370'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate (eg,<b> anaphylaxis, angioedema</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24387621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24387621'])">Ref</a></span>) and delayed hypersensitivity reactions have been reported. Delayed hypersensitivity reactions include mild reactions most often described as maculopapular or morbilliform <b>skin rashes </b>or <b>urticaria </b>occurring in ~40% of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943456','lexi-content-ref-31400463','lexi-content-ref-32374557','lexi-content-ref-24824093','lexi-content-ref-17043184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943456','lexi-content-ref-31400463','lexi-content-ref-32374557','lexi-content-ref-24824093','lexi-content-ref-17043184'])">Ref</a></span>). Severe cutaneous adverse reactions (SCARs), including<b> drug rash with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34027556','lexi-content-ref-23999760','lexi-content-ref-29276264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34027556','lexi-content-ref-23999760','lexi-content-ref-29276264'])">Ref</a></span>) and <b>Stevens-Johnson syndrome/toxic epidermal necrolysis </b>(SJS/TEN) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21702057','lexi-content-ref-26943456','lexi-content-ref-21923596','lexi-content-ref-28792264','lexi-content-ref-23113590','lexi-content-ref-22562584','lexi-content-ref-21494796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21702057','lexi-content-ref-26943456','lexi-content-ref-21923596','lexi-content-ref-28792264','lexi-content-ref-23113590','lexi-content-ref-22562584','lexi-content-ref-21494796'])">Ref</a></span>) have been documented; some events have been fatal. Lenalidomide has also been associated with other delayed hypersensitivity reactions, including <b>myocarditis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20876827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20876827'])">Ref</a></span>) and <b>hypersensitivity pneumonitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20502059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20502059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria): non–dose-related, immunologic, IgE-mediated. Delayed hypersensitivity reactions: Non–dose-related, immunologic, T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943456'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied. Morbilliform and maculopapular rashes occurred a median of 3 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943456'])">Ref</a></span>). SCARs occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21702057','lexi-content-ref-26120552','lexi-content-ref-Nice.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21702057','lexi-content-ref-26120552','lexi-content-ref-Nice.2014'])">Ref</a></span>); the median time to onset for lenalidomide-associated SJS was 24 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19047275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19047275'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity among immunomodulatory drugs (eg, thalidomide, lenalidomide, pomalidomide) is variable, despite the similarity in chemical structures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943456','lexi-content-ref-19047275','lexi-content-ref-28874903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943456','lexi-content-ref-19047275','lexi-content-ref-28874903'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Systemic amyloidosis versus multiple myeloma indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17043184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17043184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Possible association with specific HLA proteins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22150117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22150117'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Second primary malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Second primary malignancies, including hematologic (primarily acute <b>myeloid leukemia</b> [AML] and <b>myelodysplastic syndrome</b> [MDS]) and solid tumor malignancies, and non-melanoma skin cancers, have been reported with lenalidomide when used for the treatment of MDS and multiple myeloma. Overall risk is low, multifactorial, and partially related to length of patient survival and the susceptibility of multiple myeloma to additional malignancies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; may be related to immunomodulatory effects on the tumor microenvironment, favoring the escape/growth of abnormal clones that could result in second primary malignancy development. With MDS and AML, may be related to the stem-cell damaging effects through a ubiquitin/cereblon-based inhibition pathway. Another proposal is that the increased survival benefit provided by the drug increases the likelihood of development of second primary malignancies due to time, rather than a direct drug effect itself (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Multiple myeloma as indication for treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent or previous melphalan therapy or other alkylating agents with or without previous autologous stem cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of radiotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27864218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27864218'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thromboembolic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide and dexamethasone combination therapy has been associated with a significant increased risk for arterial and venous thromboembolic events (VTE) in patients with multiple myeloma. <b>Deep vein thrombosis </b>(DVT), <b>pulmonary embolism</b> (PE), <b>acute myocardial infarction</b> (MI), and <b>cerebrovascular accident</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31913498','lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31913498','lexi-content-ref-18094721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: May be related to increased platelet aggregation, single-nucleotide sequence variants and altered balance between procoagulant and anticoagulant proteins on the surface of endothelial cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31913498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31913498'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; median treatment durations prior to thromboembolic events ranged from 2 to 34 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31913498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31913498'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of arterial or VTE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying comorbidities known to increase VTE risk (eg, infection, diabetes, cardiac disease, inherited thrombophilia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapies (eg, higher doses of corticosteroids, doxorubicin, multi-agent chemotherapy, erythropoiesis stimulating agents, estrogen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31913498','lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31913498','lexi-content-ref-18094721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular comorbidities (eg, hyperlipidemia, hypertension)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immobilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of central venous catheters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18094721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18094721'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F2407590"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults receiving monotherapy and may vary based on indication. Adverse reactions are reported for newly diagnosed multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation (MM-auto-HSCT), myelodysplastic syndrome (MDS), or mantle cell lymphoma (MCL) unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (MCL, MDS: 16% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (MCL: 17%; MDS: 42%), skin rash (MCL, MDS: 22% to 36%; MM-auto-HSCT: 8%), xeroderma (MDS, MM-auto-HSCT: 11% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (4% to 13%), weight loss (MCL: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10% to 12%), constipation (13% to 24%), decreased appetite (MCL: 14%), diarrhea (MCL: 31%; MDS, MM-auto-HSCT: 39% to 49%; grades 3/4: 2% to 6%), gastroenteritis (MM-auto-HSCT: 23%), nausea (MCL, MDS: 24% to 30%; MM-auto-HSCT: 11%; grades 3/4: &lt;4%), vomiting (MCL, MDS: 10% to 12%; grades 3/4: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (MCL: 31%; MDS, MM-auto-HSCT: 9% to 11%, grades 3/4: 4% to 11%), leukopenia (MCL, MDS: 8% to 15%; MM-auto-HSCT: 32%; grades 3/4: MCL, MDS: 5% to 7%; MM-auto-HSCT: 24%), neutropenia (MCL: 49%; MDS, MM-auto-HSCT: 59% to 61%; grades 3/4: 43% to 54%)<span class="lexi-table-link-container"> (<a aria-label="Neutropenia table link" class="lexi-table-link" data-table-id="lexi-content-neutropenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-neutropenia')">table 1</a>)</span><span class="table-link" style="display:none;">Neutropenia</span>, thrombocytopenia (MCL, MM-auto-HSCT: 24% to 36%; MDS: 61%; grades 3/4: MCL: 28%; MDS: 50%; MM-auto-HSCT: 13%)<span class="lexi-table-link-container"> (<a aria-label="Thrombocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-thrombocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-thrombocytopenia')">table 2</a>)</span><span class="table-link" style="display:none;">Thrombocytopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Neutropenia" frame="border" id="lexi-content-neutropenia" rules="all">
<caption style="text-align:left;">
<b>Lenalidomide: Adverse Reaction: Neutropenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 49%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl ≥60 mL/minute: 25 mg once daily for 21 days of a 28-day treatment cycle; CrCl ≥30 mL/minute and &lt;60 mL/minute: 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mantle cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 43%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl ≥60 mL/minute: 25 mg once daily for 21 days of a 28-day treatment cycle; CrCl ≥30 mL/minute and &lt;60 mL/minute: 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mantle cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 61%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 54%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 59%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily or 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Myelodysplastic syndrome</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 53%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily or 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Myelodysplastic syndrome</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Thrombocytopenia" frame="border" id="lexi-content-thrombocytopenia" rules="all">
<caption style="text-align:left;">
<b>Lenalidomide: Adverse Reaction: Thrombocytopenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 36%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl ≥60 mL/minute: 25 mg once daily for 21 days of a 28-day treatment cycle; CrCl ≥30 mL/minute and &lt;60 mL/minute: 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mantle cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl ≥60 mL/minute: 25 mg once daily for 21 days of a 28-day treatment cycle; CrCl ≥30 mL/minute and &lt;60 mL/minute: 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mantle cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">All grades: 61%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily or 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Myelodysplastic syndrome</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 3/4: 50%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily or 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Myelodysplastic syndrome</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">148</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (MM-auto-HSCT: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (MCL, MDS: 14% to 15%; MM-auto-HSCT: 30%), dizziness (MDS: 20%), fatigue (MCL, MDS: 31% to 34%; MM-auto-HSCT: 11%), headache (MDS: 20%; MM-auto-HSCT: 9%), paresthesia (MM-auto-HSCT: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (MCL: 8%; MDS: 22%), back pain (MCL, MDS: 13% to 21%), limb pain (MDS: 11%), muscle cramps (MDS: 18%), muscle spasm (MCL: 13%; MM-auto-HSCT: 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (MDS: 6%; MM-auto-HSCT: 47%), cough (20% to 28%), dyspnea (including exacerbations: MCL, MDS: 17% to 18%; MM-auto-HSCT: 6%), epistaxis (MDS: 15%), nasopharyngitis (MDS: 23%; MM-auto-HSCT: 35%), pharyngitis (MDS: 16%), pneumonia (11% to 17%; can be lobar pneumonia), rhinitis (MDS, MM-auto-HSCT: 7% to 15%), sinusitis (MDS, MM-auto-HSCT: 8% to 14%; can be acute sinusitis), upper respiratory tract infection (11% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (20% to 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (MCL: ≥2%), chest pain (MDS: 5%), deep vein thrombosis (MCL, MM-auto-HSCT: 2% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Deep Vein Thrombosis table link" class="lexi-table-link" data-table-id="lexi-content-deep-vein-thrombosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-deep-vein-thrombosis')">table 3</a>)</span><span class="table-link" style="display:none;">Deep Vein Thrombosis</span>, edema (MDS: 10%), heart failure (MCL), hypertension (MDS: 6%), hypotension (MCL: 7%), palpitations (MDS: 5%), pulmonary embolism (MCL, MM-auto-HSCT: 1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Pulmonary Embolism table link" class="lexi-table-link" data-table-id="lexi-content-pulmonary-embolism" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pulmonary-embolism')">table 4</a>)</span><span class="table-link" style="display:none;">Pulmonary Embolism</span>, supraventricular tachycardia (MCL: ≥2%), swelling of extremities (MDS: 8%), syncope (MDS: grades 3/4: 1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Deep Vein Thrombosis" frame="border" id="lexi-content-deep-vein-thrombosis" rules="all">
<caption style="text-align:left;">
<b>Lenalidomide: Adverse Reaction: Deep Vein Thrombosis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl ≥60 mL/minute: 25 mg once daily for 21 days of a 28-day treatment cycle; CrCl ≥30 mL/minute and &lt;60 mL/minute: 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mantle cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pulmonary Embolism" frame="border" id="lexi-content-pulmonary-embolism" rules="all">
<caption style="text-align:left;">
<b>Lenalidomide: Adverse Reaction: Pulmonary Embolism</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl ≥60 mL/minute: 25 mg once daily for 21 days of a 28-day treatment cycle; CrCl ≥30 mL/minute and &lt;60 mL/minute: 10 mg once daily for 21 days of a 28-day treatment cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mantle cell lymphoma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma of skin (MCL: ≥2%), cellulitis (MCL, MDS: 2% to 5%), diaphoresis (MDS: 7%), ecchymoses (MDS: 5%), erythema of skin (MDS: 5%), night sweats (MDS: 8%), squamous cell carcinoma of skin (MCL: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (MCL: 7%), hypocalcemia (MCL: 3%), hypomagnesemia (MDS: 6%), hyponatremia (MCL: 2%), hypothyroidism (MDS: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (MDS: 10%), <i>Clostridioides difficile</i> colitis (MCL: ≥2%), dysgeusia (MDS: 6%), oral herpes simplex infection (MCL), upper abdominal pain (MDS, MM-auto-HSCT: 7% to 8%), xerostomia (MDS: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (MDS: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (MDS: 8%), febrile neutropenia (2% to 6%; grades 3/4: 2% to 6%), granulocytopenia (MDS: grades 3/4: 2%), lymphocytopenia (MCL, MM-auto-HSCT: 4% to 7%; grades 3/4: 4%), myelodysplastic syndrome (MM-auto-HSCT: 1%; grades 3/4: &lt;1%), pancytopenia (MM-auto-HSCT: 4%; MDS, MM-auto-HSCT: grades 3/4: 2%), tumor flare (MCL: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (MM-auto-HSCT: 1%), increased serum alanine aminotransferase (MDS: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia (MCL: 1%), herpes zoster infection (including reactivation; MM-auto-HSCT: 10%), infection (MM-auto-HSCT: 6%)<span class="lexi-table-link-container"> (<a aria-label="Infection table link" class="lexi-table-link" data-table-id="lexi-content-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infection')">table 5</a>)</span><span class="table-link" style="display:none;">Infection</span>, sepsis (MCL, MM-auto-HSCT: 1% to 2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infection" frame="border" id="lexi-content-infection" rules="all">
<caption style="text-align:left;">
<b>Lenalidomide: Adverse Reaction: Infection</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lenalidomide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Multiple myeloma, maintenance therapy following autologous hematopoietic stem cell transplantation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">293</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">280</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (MCL), depression (MDS: 5%), hypoesthesia (MDS: 7%), insomnia (MDS: 10%), lethargy (MCL), myasthenia (MCL: 6%), pain (MDS: 7%), peripheral neuropathy (MDS, MM-auto-HSCT: 5% to 10%; grades 3/4: 1%), rigors (MDS: 6%), vertigo (MCL)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (MDS, MM-auto-HSCT: 6% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (MCL: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Chronic obstructive pulmonary disease (MCL: ≥2%), Dyspnea on exertion (MDS: 7%), hypoxia (MCL: 2%), oropharyngeal pain (MCL: 10%), pleural effusion (MCL: 7%), respiratory distress (MCL: 1%), respiratory tract infection (MM-auto-HSCT: 3%), rhinorrhea (MM-auto-HSCT: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure (MDS: grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, atrial fibrillation (including aggravated atrial fibrillation), bradycardia, cardiac disorder (aortic disorder), cardiogenic shock, cardiomyopathy, superficial thrombophlebitis, supraventricular cardiac arrhythmia, tachyarrhythmia, ventricular dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Sweet syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Graves disease, hypernatremia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abscess of rectum and/or peri-rectal area, biliary obstruction, cholecystitis (may be acute), colonic polyps, diverticulitis of the gastrointestinal tract, dysphagia, gastritis, gastroesophageal reflux disease, gastrointestinal hemorrhage (including upper gastrointestinal hemorrhage), infection of mouth, inguinal hernia (obstructive), intestinal obstruction (small intestine), intestinal perforation, irritable bowel syndrome, ischemic colitis, melena, pancreatitis, rectal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azotemia, hematuria, pelvic pain, prostate carcinoma, urinary tract infection with sepsis, urolithiasis (ureter)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acquired blood coagulation disorder, acute leukemia, bone marrow depression, hemolysis, hemolytic anemia, malignant lymphoma, myeloid leukemia (acute), splenic infarction, warm antibody immunohemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection, herpes virus infection, kidney infection, septic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, aphasia, cerebellar infarction, cerebral infarction, cerebrovascular accident, confusion, dysarthria, falling, impaired consciousness, migraine, subarachnoid hemorrhage, transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (including exacerbation), bone fracture (cervical, femoral neck fracture, femur fracture, pelvic fracture, rib fracture, spinal cord compression), calcium pyrophosphate deposition disease, gout, gouty arthritis, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otic infection</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchogenic carcinoma, interstitial lung disease, malignant neoplasm of lung, pulmonary edema, pulmonary infiltrates, respiratory failure, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Mass (renal), nodule</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis (Carver 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Barley 2016), toxic epidermal necrolysis (Barley 2016), urticaria (Uchiyama 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperthyroidism (Blair 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (Nojkov 2012), cholestatic hepatitis, hepatic cytolysis, hepatic failure, toxic hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Uchiyama 2014), drug reaction with eosinophilia and systemic symptoms (Osada 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Graft-versus-host disease, organ transplant rejection</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Progressive multifocal leukoencephalopathy (Anderson 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypersensitivity pneumonitis (Lerch 2010), pneumonitis</p></div>
<div class="block coi drugH1Div" id="F2407586"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe hypersensitivity (eg, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide or any component of the formulation; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Platelet count &lt;50,000/mm<sup>3</sup> (in patients with myelodysplastic syndromes); hypersensitivity to thalidomide or pomalidomide; patients capable of becoming pregnant; breastfeeding; male patients unable to follow or comply with required contraceptive measures.</p></div>
<div class="block war drugH1Div" id="F2407587"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause dizziness or fatigue; caution patients about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor flare: Tumor flare reactions, including fatalities, have been observed in studies of lenalidomide for the treatment of chronic lymphocytic leukemia (CLL) and lymphomas; clinical presentation includes low grade fever, pain, rash, and tender lymph node swelling. In patients with mantle cell lymphoma, follicular lymphoma, and/or marginal zone lymphoma, tumor flare may mimic disease progression. In clinical trials, the majority of tumor flare events occurred in the first cycle of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (with fatalities) has been reported with lenalidomide. Patients with a high tumor burden may be at risk for tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, lenalidomide has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; may experience an increased rate of toxicities due to reduced clearance and increased half-life.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mantle cell lymphoma: An increased incidence of early deaths (within 20 weeks) was reported in one study of patients receiving lenalidomide for the treatment of mantle cell lymphoma. Risk factors for early death include high tumor burden, mantle cell lymphoma international prognostic index (MIPI) score at diagnosis, and high WBC count (≥10,000/mm<sup>3</sup>) at baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple myeloma: An increase in mortality was noted in 2 clinical studies in patients with multiple myeloma who received pembrolizumab in combination with a thalidomide analogue and dexamethasone. Pembrolizumab should not be used to treat multiple myeloma in combination with a thalidomide analogue and dexamethasone unless as part of a clinical trial.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stem cell mobilization: Lenalidomide use (≥4 cycles) may decrease the number of CD34+ cells collected for autologous hematopoietic cell transplant. Transplant eligible patients receiving lenalidomide should be referred to an appropriate transplant center in order to optimize the timing of stem cell collection. Cyclophosphamide in combination with G-CSF or G-CSF in combination with a CXC chemokine receptor 4 inhibitor (eg, plerixafor) may be considered when CD34+ cell collection is impaired.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Certain adverse reactions (DVT, PE, atrial fibrillation, renal failure) are more likely in patients &gt;65 years of age; in some studies, the incidence of grade 3 or 4 adverse reactions was higher in older adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: If used in patients between 12 to 18 years of age, the parent or legal guardian must agree to ensure compliance with the Lenalidomide REMS program.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: In a clinical trial comparing lenalidomide versus chlorambucil single agent therapy in patients &gt;65 years of age with chronic lymphocytic leukemia patients (not an FDA-approved indication), increased mortality was observed in the lenalidomide treatment arm. Atrial fibrillation, cardiac failure, and MI were observed more frequently in lenalidomide-treated patients; lenalidomide (alone or in combination) is not currently recommended for first-line treatment of CLL.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: Due to the embryo-fetal risk, lenalidomide is only available through a restricted program under the Lenalidomide REMS program. Prescribers and pharmacies must be certified with the program to prescribe or dispense lenalidomide. Lenalidomide should only be prescribed to patients who can understand and comply with the conditions of the Lenalidomide REMS program.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood donation: Patients should be advised not to donate blood during lenalidomide treatment and for 4 weeks following completion of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose intolerance: Product may contain lactose; avoid use in patients with congenital lactase deficiency, glucose-galactose malabsorption, or glucose intolerance.</p></div>
<div class="block foc drugH1Div" id="F2407623"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 2.5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 10 mg, 15 mg, 20 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg</p></div>
<div class="block geq drugH1Div" id="F2407574"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322927"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lenalidomide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $949.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $949.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $949.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $949.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $949.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $949.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Revlimid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $999.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $999.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $999.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $999.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $999.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $999.87</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868750"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 2.5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 10 mg, 15 mg, 20 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revlimid: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg</p></div>
<div class="block accres drugH1Div" id="F11234038"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">In Canada, distribution is restricted through RevAid (www.RevAid.ca or 1-888-738-2431).</p></div>
<div class="block adm drugH1Div" id="F2407615"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer at about the same time each day with water; administer with or without food. Swallow capsule whole; do not break, open, or chew.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Missed doses:</i> May administer a missed dose if within 12 hours of usual dosing time. If greater than 12 hours, patient should skip dose for that day and resume usual dosing the following day. Patient should <b>not</b> take 2 doses to make up for a missed dose.</p></div>
<div class="block hazard drugH1Div" id="F49104526"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F7874837"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021880s067lbl.pdf%23page%3D48&amp;token=EyfsCGyEpQnkm8RXsppXJ%2FdzWskX9jvgjl7FR9AMijmH%2BhBJCaSZBrfzcAvVZPP%2BLYkw3V9mBioNHY2BNd1RTG3nW2l2XgLf1BZD4XxSIhp9oL%2FASR%2Bcx8PtTS0fNjhG&amp;TOPIC_ID=9822" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf#page=48</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F2407578"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Follicular lymphoma, previously treated:</b> Treatment of previously treated follicular lymphoma (in combination with a rituximab product) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mantle cell lymphoma, relapsed or progressive:</b> Treatment of mantle cell lymphoma that has relapsed or progressed after 2 prior therapies (one of which included bortezomib) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Marginal zone lymphoma, previously treated:</b> Treatment of previously treated marginal zone lymphoma (in combination with a rituximab product) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma:</b> Treatment of multiple myeloma (in combination with dexamethasone) in adults; maintenance therapy following autologous hematopoietic cell transplantation in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic syndromes, International Prognostic Scoring System low-risk or intermediate-1-risk, with deletion 5q:</b> Treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q (del [5q]) cytogenetic abnormality with or without additional cytogenetic abnormalities in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Lenalidomide is not indicated and is not recommended for the treatment of chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (manufacturer’s labeling).</p></div>
<div class="block off-label drugH1Div" id="F25473682"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic lymphocytic leukemia, relapsed or refractory; Diffuse large B-cell lymphoma, relapsed or refractory; Myelodysplastic syndromes, International Prognostic Scoring System low-risk or intermediate-1-risk, without deletion 5q; Smoldering multiple myeloma, high risk; Systemic light chain amyloidosis, previously treated</p></div>
<div class="block mst drugH1Div" id="F3401642"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lenalidomide may be confused with leflunomide, pomalidomide, thalidomide.</p>
<p style="text-indent:-2em;margin-left:4em;">Revlimid may be confused with revefenacin, Thalomid.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Revlimid may be confused with Revolade, a brand name for eltrombopag [Canada].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299581"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F2407598"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abatacept: Anti-TNF Agents may enhance the immunosuppressive effect of Abatacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): May enhance the thrombogenic effect of Lenalidomide. Management: Consider using venous thromboembolism prophylaxis (eg, low-molecular weight heparin or warfarin [INR 2.0-3.0]) in patients with multiple myeloma who are receiving lenalidomide and dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Lenalidomide may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythropoiesis-Stimulating Agents: May enhance the thrombogenic effect of Lenalidomide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the thrombogenic effect of Lenalidomide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pembrolizumab: May enhance the adverse/toxic effect of Thalidomide Analogues. Specifically, mortality may be increased when this combination is used for treatment of refractory multiple myeloma.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307978"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to therapy. Patients who could become pregnant should be treated only if they are able to comply with the conditions of the Lenalidomide REMS program. Patients who could become pregnant must avoid pregnancy beginning 4 weeks prior to therapy, during therapy, during therapy interruptions, and for at least 4 weeks after therapy is discontinued. Two negative pregnancy tests (sensitivity of at least 50 milliunits/mL) are required prior to starting lenalidomide treatment. The first test must be done 10 to 14 days prior to therapy, and the second within 24 hours prior to beginning therapy; additional pregnancy testing must be done weekly during the first 4 weeks, and every 4 weeks (every 2 weeks for patients with irregular menstrual cycles) thereafter. Lenalidomide must be immediately discontinued for a missed period, abnormal pregnancy test, or abnormal menstrual bleeding; refer patient to a reproductive toxicity specialist if pregnancy occurs during treatment. False-positive pregnancy tests have been reported during lenalidomide therapy (Castaneda 2018; Helm 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Two forms of effective/reliable contraception (eg, tubal ligation, IUD, hormonal birth control methods, male latex or synthetic condom, diaphragm, or cervical cap) or total abstinence from heterosexual intercourse must be used unless the patient is infertile or has had a hysterectomy.</p>
<p style="text-indent:0em;margin-top:2em;">Lenalidomide is also present in semen. Patients (including those vasectomized) with partners who could become pregnant should use a latex or synthetic condom during any sexual contact with patients who could become pregnant, during lenalidomide treatment, during treatment interruptions, and for 4 weeks after discontinuation. Patients should not donate sperm during, for 4 weeks after treatment, and during lenalidomide therapy interruptions.</p></div>
<div class="block pri drugH1Div" id="F2407581"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to lenalidomide may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Use of lenalidomide is contraindicated in pregnant patients. Lenalidomide is a thalidomide analogue, which is known to cause severe, life-threatening human birth defects. Exposure to lenalidomide during pregnancy may cause birth defects or embryo-fetal death. Discontinue immediately if pregnancy occurs during treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor outcomes following exposure to lenalidomide during pregnancy, including pregnant partners of male patients, is ongoing. Any suspected fetal exposure should be reported to the FDA via the MedWatch program (1-800-FDA-1088) and to the REM Call Center (1-888-423-5436).</p></div>
<div class="block brc drugH1Div" id="F2407585"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lenalidomide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F2407617"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (mantle cell lymphoma - weekly for the first cycle, every 2 weeks during cycles 2 to 4 and monthly thereafter; myelodysplastic syndrome - weekly for first 8 weeks and at least monthly thereafter; multiple myeloma - weekly for the first 2 cycles, every 2 weeks during the third cycle and monthly thereafter; follicular and marginal zone lymphoma – weekly for the first 3 weeks in cycle 1 and every 2 weeks in cycles 2 to 4 and monthly thereafter; also monitor as clinically indicated); renal function (eg, serum creatinine), LFTs (periodically). Thyroid function tests (TSH at baseline then every 2 to 3 months during lenalidomide treatment [Hamnvik 2011]). ECG when clinically indicated. Monitor for signs and symptoms of infection (if neutropenic), bleeding or bruising, hepatotoxicity, secondary malignancies, thromboembolism (eg, shortness of breath, chest pain, arm or leg swelling), dermatologic toxicity, tumor lysis syndrome, or hypersensitivity. Monitor for tumor flare reaction in patients with mantle cell lymphoma, follicular lymphoma, and/or marginal zone lymphoma. Monitor for development of second primary malignancies. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients who could become pregnant: Pregnancy test 10 to 14 days <b>and</b> 24 hours prior to initiating therapy, weekly during the first 4 weeks of treatment, then every 2 to 4 weeks through 4 weeks after therapy discontinued.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F2407602"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lenalidomide has immunomodulatory, antiangiogenic, and antineoplastic characteristics via multiple mechanisms. It selectively inhibits secretion of proinflammatory cytokines (potent inhibitor of tumor necrosis factor-alpha secretion); enhances cell-mediated immunity by stimulating proliferation of anti-CD3 stimulated T cells (resulting in increased IL-2 and interferon gamma secretion); inhibits trophic signals to angiogenic factors in cells. Inhibits the growth of myeloma, myelodysplastic, and lymphoma tumor cells by inducing cell cycle arrest and cell death. The addition of lenalidomide to rituximab increases antibody dependent cell-mediated cytotoxicity in follicular lymphoma and marginal zone lymphoma and increases tumor cell apoptosis in follicular lymphoma (compared to rituximab alone).</p></div>
<div class="block phk drugH1Div" id="F2407604"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~30%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: MDS or myeloma patients: 0.5 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~82%; as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51198308"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life is increased 3-fold in moderate (CrCl 30 to 49 mL/minute) to severe (CrCl &lt;30 mL/minute) kidney impairment and increased ~4.5-fold in hemodialysis patients, compared to healthy patients. There is a 66% to 75% decrease in drug clearance in patients with moderate (CrCl 30 to 49 mL/minute) and severe (CrCl &lt;30 mL/minute) kidney impairment compared with healthy subjects. Hemodialysis patients had an 80% decrease in drug clearance compared with healthy subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539966"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lenadair | Revlimid</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hemalen | Kyledex | Kylend | Ladevina | Ledamin | Ledane | Lenalinova | Lenomel | Lunadin | Mizarid | Myelenz | Renged | Revlimid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid +pharma | Lenalidomid fresenius kabi | Lenalidomid G.L | Lenalidomid grindeks | Lenalidomid mylan | Lenalidomid zentiva | Lenalidomide accord | Lenalidomide sandoz | Lenalidomide stada | Revlimid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cipla lenalidomide | Lenalide | Lenalidomide sandoz | Revlimid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid Accord | Lenalidomide ab | Lenalidomide krka | Lenalidomide mylan | Lenalidomide sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid Accord | Lenalidomide alvogen | Lenalidomide g.l. | Lenalidomide pharmascience | Revlimid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid Accord | Lenalidomid bms | Lenalidomid devatis | Lenalidomid sandoz | Lenalidomid spirig hc | Lenalidomid teva | Lenalidomid zentiva | Revlimid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Adeline | Lenalidomida | Lenangio | Revlimid</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Domide | Ladevina | Lenoside | Lizgram | Perlara | Revlimid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid sandoz | Lenalidomid stada | Lenalidomid teva | Lenalidomid zentiva | Lenalidomide accord | Lenalidomide glenmark | Lenalidomide mylan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid axiromed | Revlimid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ladevina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ladevina | Lenalidomida | Nuvyor | Revlimid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide auxilia | Lenalidomide grindeks</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Immunomide | Revlimid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomida accord | Lenalidomida aurovitas | Lenalidomida cipla | Lenalidomida dr. reddys | Lenalidomida glenmark | Lenalidomida kern | Lenalidomida mylan | Lenalidomida sandoz | Lenalidomida stada | Lenalidomide tecnigen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid avansor | Lenalidomid zentiva | Lenalidomide accord | Lenalidomide fresenius kabi | Lenalidomide grindeks | Lenalidomide mylan | Lenalidomide orion | Lenalidomide sandoz | Lenalidomide stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide arrow | Lenalidomide eg | Lenalidomide mylan | Lenalidomide ohre pharma | Lenalidomide zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide ranbaxy | Lenalidomide sandoz | Lenalidomide zentiva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lenalid | Revlimid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid Accord | Revlimid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid onkogen | Lenalidomid teva | Lenalidomide accord | Lenalidomide g.l. | Lenalidomide mylan | Lenalidomide sandoz | Lenalidomide stada | Lignaron | Revlimid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide clonmel | Lenalidomide rowex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adlinod | Celomide | Kabilen | Laviat | Lenangio | Lenid | Lenmid | Lenofect | Lenome | Lenomust | Lenzest | Myelomide | Relidomide</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kleder | Lenalidomide accord | Lenalidomide aurobindo | Lenalidomide dr. reddy's | Lenalidomide grindeks | Lenalidomide medac | Lenalidomide mylan | Lenalidomide sandoz | Lenalidomide zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Sotira</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Lenoside</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alvogen lenalidomide | Lenaldo | Lenaloma | Revlimid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide alvogen | Lenalidomide g.l. | Lenalidomide stada | Lenalidomide zentiva | Polalid | Revlimid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide eg | Lenalidomide mylan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide alvogen | Lenalidomide grindeks | Lenalidomide norameda | Lenalidomide stada | Revlimid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lenangio | Revlimid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide aurobindo | Lenalidomide CF | Lenalidomide mylan | Lenalidomide sandoz | Revlimid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid zentiva | Lenalidomide mylan | Lenalidomide sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bomilen | Domidalid | Ladevina | Nuvyor | Revlimid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide accord | Lenalidomide glenmark | Lenalidomide grindeks | Lenalidomide mylan | Lenalidomide sandoz | Lenalidomide zentiva | Linorion | Revlimid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomida accord | Lenalidomida fresenius kabi | Lenalidomida generis | Lenalidomida pharmakern | Lenalidomida sandoz | Lenalidomida stada | Lenalidomida tecnigen | Lenalidomida teva | Revlimid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomida bauel top | Lenalidomida cellofarm | Lenalidomida gebina | Lenalidomida lkm | Lenalidomida prosalud | Lenalidomida tuteur | Revlimid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Revlimid</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomida alvogen | Lenalidomida labormed | Lenalidomide accord | Lenalidomide sandoz | Revlimid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid | Lenalidomide nativ | Lenangio | Metiblastan | Revlimid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide spc | Lenamid | Lidova | Revlimid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid avansor | Lenalidomid cipla | Lenalidomid medical valley | Lenalidomid sun | Lenalidomid zentiva | Lenalidomide accord | Lenalidomide glenmark | Lenalidomide mylan | Lenalidomide newbury | Lenalidomide orion | Lenalidomide sandoz | Lenalidomide stada | Revlimid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lenangio | Revlimid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid alkaloid int | Lenalidomid sandoz | Lenalidomide accord</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomid alvogen | Lenalidomid glenmark | Lenalidomid grindeks | Lenalidomid pharmevid | Lenalidomid sandoz | Lenalidomid stada | Lenalidomide accord | Lignaron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide alvogen | Lenangio | Revlimid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomide neapolis | Revlimid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lenatu | Paused | Revlimid | Rivelime</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Leavdo | Lenli | Revlimid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lenalidol | Lenalidomide-vista | Lenangio</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lenalidomida libra | Myelenz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eurolen | Lenalidomide cipla | Lenalidomide drl | Lenalidomide forrester | Lenmid | Myelid | Mylomid | Revlimid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21702057">
<a name="21702057"></a>Allegra A, Alonci A, Penna G, et al. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. <i>Hematol Oncol</i>. 2012;30(1):41-45. doi:10.1002/hon.1000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21702057/pubmed" id="21702057" target="_blank">21702057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30704932">
<a name="30704932"></a>Anderson S, Kiernan M, Ho PJ. Lenalidomide-related progressive multifocal leukoencephalopathy: A case report and review of drug-related cases in multiple myeloma. <i>Clin Lymphoma Myeloma Leuk</i>. 2019;19(4):e169-e171. doi:10.1016/j.clml.2018.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/30704932/pubmed" id="30704932" target="_blank">30704932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22571202">
<a name="22571202"></a>Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. <i>N Engl J Med.</i> 2012;366(19):1782-1791. doi:10.1056/NEJMoa1114138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22571202/pubmed" id="22571202" target="_blank">22571202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23270003">
<a name="23270003"></a>Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. <i>J Clin Oncol.</i> 2013;31(5):584-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23270003/pubmed" id="23270003" target="_blank">23270003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943456">
<a name="26943456"></a>Barley K, He W, Agarwal S, Jagannath S, Chari A. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. <i>Leuk Lymphoma</i>. 2016;57(11):2510-2515. doi:10.3109/10428194.2016.1151507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26943456/pubmed" id="26943456" target="_blank">26943456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12969978">
<a name="12969978"></a>Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. <i>Blood. </i>2004;103(1):20-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/12969978/pubmed" id="12969978" target="_blank">12969978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25184863">
<a name="25184863"></a>Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. <i>N Engl J Med</i>. 2014;371(10):906-917. doi:10.1056/NEJMoa1402551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/25184863/pubmed" id="25184863" target="_blank">25184863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31534740">
<a name="31534740"></a>Blair RA, Leaf RK, Leaf DE. A case of severe hypothyroidism due to lenalidomide. <i>Clin Case Rep</i>. 2019;7(9):1747-1749. doi:10.1002/ccr3.2362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31534740/pubmed" id="31534740" target="_blank">31534740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21923596">
<a name="21923596"></a>Boruah PK, Bolesta S, Shetty SM. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. <i>Pharmacotherapy</i>. 2011;31(9):925. doi:10.1592/phco.31.9.925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21923596/pubmed" id="21923596" target="_blank">21923596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27286995">
<a name="27286995"></a>Bridoux F, Chen N, Moreau S, et al. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Chemother Pharmacol.</i> 2016;78(1):173-182. doi:10.1007/s00280-016-3068-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27286995/pubmed" id="27286995" target="_blank">27286995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20876827">
<a name="20876827"></a>Carver JR, Nasta S, Chong EA, et al. Myocarditis during lenalidomide therapy. <i>Ann Pharmacother</i>. 2010;44(11):1840-1843. doi:10.1345/aph.1P044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20876827/pubmed" id="20876827" target="_blank">20876827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047275">
<a name="19047275"></a>Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.<i> J Clin Oncol</i>. 2009;27(1):156-157. doi:10.1200/JCO.2008.20.3737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/19047275/pubmed" id="19047275" target="_blank">19047275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28792264">
<a name="28792264"></a>Castaneda C, Minton N, Mezo M, et al. False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States. <i>Leuk Lymphoma</i>. 2018;59(4):1025‐1026. doi:10.1080/10428194.2017.1361030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/28792264/pubmed" id="28792264" target="_blank">28792264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31913498">
<a name="31913498"></a>Chakraborty R, Bin Riaz I, Malik SU, et al. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i>. 2020;126(8):1640-1650. doi:10.1002/cncr.32682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31913498/pubmed" id="31913498" target="_blank">31913498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17088571">
<a name="17088571"></a>Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. <i>J Clin Oncol.</i> 2006;24(34):5343-5349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17088571/pubmed" id="17088571" target="_blank">17088571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32476520">
<a name="32476520"></a>Chen CI, Cao Y, Trudel S, et al. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines. <i>Leuk Lymphoma</i>. 2020;61(8):1860-1868. doi:10.1080/10428194.2020.1747064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32476520/pubmed" id="32476520" target="_blank">32476520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22955172">
<a name="22955172"></a>Chen N, Kasserra C, Reyes J, et al. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. <i>Cancer Chemother Pharmacol.</i> 2012;70(5):717-725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22955172/pubmed" id="22955172" target="_blank">22955172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17954615">
<a name="17954615"></a>Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. <i>J Clin Pharmacol.</i> 2007;47(12):1466-1475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17954615/pubmed" id="17954615" target="_blank">17954615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31400463">
<a name="31400463"></a>Demir S, Gelincik A, Coskun R, et al. A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions. <i>Ann Allergy Asthma Immunol</i>. 2019;123(4):394-397. doi:10.1016/j.anai.2019.07.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31400463/pubmed" id="31400463" target="_blank">31400463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20564094">
<a name="20564094"></a>Dimopoulos M, Alegre A, Stadtmauer EA et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. <i>Cancer.</i> 2010;116(16):3807-3814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20564094/pubmed" id="20564094" target="_blank">20564094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14645435">
<a name="14645435"></a>Dimopoulos MA, Anagnostopoulos A, and Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. <i>J Clin Oncol.</i> 2003;21(23):4444-4454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/14645435/pubmed" id="14645435" target="_blank">14645435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26659916">
<a name="26659916"></a>Dimopoulos MA, Cheung MC, Roussel M, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. <i>Haematologica</i>. 2016c;101(3):363-370. doi:10.3324/haematol.2015.133629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26659916/pubmed" id="26659916" target="_blank">26659916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20192988">
<a name="20192988"></a>Dimopoulos MA, Christoulas D, Roussou M, et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>Eur J Haematol</i>. 2010;85(1):1-5. doi:10.1111/j.1600-0609.2010.01432.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20192988/pubmed" id="20192988" target="_blank">20192988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32887873">
<a name="32887873"></a>Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer J</i>. 2020;10(9):91. doi:10.1038/s41408-020-00357-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32887873/pubmed" id="32887873" target="_blank">32887873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27705267">
<a name="27705267"></a>Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016a;375(14):1319-1331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27705267/pubmed" id="27705267" target="_blank">27705267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36599114">
<a name="36599114"></a>Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. <i>J Clin Oncol</i>. 2023;41(8):1590-1599. doi:10.1200/JCO.22.00940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/36599114/pubmed" id="36599114" target="_blank">36599114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22323483">
<a name="22323483"></a>Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood.</i> 2012;9(12):2764-2767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22323483/pubmed" id="22323483" target="_blank">22323483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016b;34(13):1544-1557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18032762">
<a name="18032762"></a>Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. <i>N Engl J Med.</i> 2007;357(21):2123-2132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18032762/pubmed" id="18032762" target="_blank">18032762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dispenzieri.1">
<a name="Dispenzieri.1"></a>Dispenzieri A, Lacy M, Zeldenrust SR, et al. Follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone. <i>Blood</i>. 2008;112(11):1737. doi:10.1182/blood.V112.11.1737.1737</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17008538">
<a name="17008538"></a>Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. <i>Blood.</i> 2007;109(2):465-470. doi:10.1182/blood-2006-07-032987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17008538/pubmed" id="17008538" target="_blank">17008538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28017406">
<a name="28017406"></a>Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/28017406/pubmed" id="28017406" target="_blank">28017406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32393732">
<a name="32393732"></a>Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). <i>Blood Cancer J</i>. 2020;10(5):53. doi:10.1038/s41408-020-0311-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32393732/pubmed" id="32393732" target="_blank">32393732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20880113">
<a name="20880113"></a>Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. <i>Br J Haematol.</i> 2010;151(4):410-412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20880113/pubmed" id="20880113" target="_blank">20880113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29150421">
<a name="29150421"></a>Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i>. 2018;131(3):301-310. doi:10.1182/blood-2017-07-795047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/29150421/pubmed" id="29150421" target="_blank">29150421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31141632">
<a name="31141632"></a>Facon T, Kumar S, Plesner T, et al; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. <i>N Engl J Med</i>. 2019;380(22):2104-2115. doi:10.1056/NEJMoa1817249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31141632/pubmed" id="31141632" target="_blank">31141632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33763699">
<a name="33763699"></a>Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i>. 2021;137(26):3616-3628. doi:10.1182/blood.2020008787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/33763699/pubmed" id="33763699" target="_blank">33763699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Faderl.1">
<a name="Faderl.1"></a>Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. <i>Cancer.</i> 2004;101(2): 226-241.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21753188">
<a name="21753188"></a>Fenaux P, Giagounidis A, Selleslag D, et al. A Randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. <i>Blood.</i> 2011;118(14):3765-3776. doi:10.1182/blood-2011-01-330126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21753188/pubmed" id="21753188" target="_blank">21753188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18334676">
<a name="18334676"></a>Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Blood. </i>2008;111(11): 5291-5297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18334676/pubmed" id="18334676" target="_blank">18334676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15891887">
<a name="15891887"></a>Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. <i>Ann Hematol.</i> 2005;84(9):569-571.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/15891887/pubmed" id="15891887" target="_blank">15891887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24002500">
<a name="24002500"></a>Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. <i>J Clin Oncol</i>. 2013;31(29):3688-3695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24002500/pubmed" id="24002500" target="_blank">24002500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26195701">
<a name="26195701"></a>Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma. <i>J Clin Oncol</i>. 2015;33(25):2803-2811. doi:10.1200/JCO.2014.59.5363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26195701/pubmed" id="26195701" target="_blank">26195701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19245430">
<a name="19245430"></a>Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. <i>Br J Haematol. </i>2009;145(3):344-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/19245430/pubmed" id="19245430" target="_blank">19245430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst.</i> 2011;103(21):1572-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32989742">
<a name="32989742"></a>Helm MF, Koc Z, Washington A, Legro RS, Miller JJ. A positive serum pregnancy test in a patient on the potent teratogen lenalidomide: a distressing result provides a valuable learning opportunity. <i>Int J Dermatol</i>. 2021;60(3):e96-e98. doi:10.1111/ijd.15197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32989742/pubmed" id="32989742" target="_blank">32989742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17984315">
<a name="17984315"></a>Hussain S, Browne R, Chen J, Parekh S. Lenalidomide-induced severe hepatotoxicity. <i>Blood</i>. 2007;110(10):3814. doi:10.1182/blood-2007-06-097758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17984315/pubmed" id="17984315" target="_blank">17984315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22665938">
<a name="22665938"></a>Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood.</i> 2012;120(9):1801-1809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22665938/pubmed" id="22665938" target="_blank">22665938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30477009">
<a name="30477009"></a>Kazandjian D, Korde N, Mailankody S, et al. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial. <i>JAMA Oncol</i>. 2018;4(12):1781-1783. doi:10.1001/jamaoncol.2018.5457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/30477009/pubmed" id="30477009" target="_blank">30477009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520. doi:10.1200/JCO.19.01461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26181891">
<a name="26181891"></a>Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. <i>JAMA Oncol</i>. 2015;1(6):746-754. doi:10.1001/jamaoncol.2015.2010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26181891/pubmed" id="26181891" target="_blank">26181891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22422823">
<a name="22422823"></a>Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood.</i> 2012;119(19):4375-4382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22422823/pubmed" id="22422823" target="_blank">22422823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509819">
<a name="15509819"></a>Kyle RA, Rajkumar SV. Multiple myeloma. <i>N Engl J Med.</i> 2004;351(18):1860-1873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/15509819/pubmed" id="15509819" target="_blank">15509819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33739404">
<a name="33739404"></a>Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i>. 2021;137(22):3027-3036. doi:10.1182/blood.2020009507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/33739404/pubmed" id="33739404" target="_blank">33739404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21835953">
<a name="21835953"></a>Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood.</i> 2012;119(4):933-939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21835953/pubmed" id="21835953" target="_blank">21835953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32374557">
<a name="32374557"></a>Lazzarato I, Gonzalez-Muñoz M, Heredia R, et al. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. <i>Eur Ann Allergy Clin Immunol</i>. 2020;52(5):235-237. doi:10.23822/EurAnnACI.1764-1489.134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32374557/pubmed" id="32374557" target="_blank">32374557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24824093">
<a name="24824093"></a>Lee MJ, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. <i>Br J Haematol</i>. 2014;167(1):127-131. doi:10.1111/bjh.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24824093/pubmed" id="24824093" target="_blank">24824093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30897038">
<a name="30897038"></a>Leonard JP, Trneny M, Izutsu K, et al; AUGMENT Trial Investigators. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. <i>J Clin Oncol</i>. 2019;37(14):1188-1199. doi:10.1200/JCO.19.00010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/30897038/pubmed" id="30897038" target="_blank">30897038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20502059">
<a name="20502059"></a>Lerch E, Györik S, Feilchenfeldt J, Mazzucchelli L, Quadri F. A case of lenalidomide-induced hypersensitivity pneumonitis. <i>Onkologie</i>. 2010;33(5):249-252. doi:10.1159/000305213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20502059/pubmed" id="20502059" target="_blank">20502059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24668858">
<a name="24668858"></a>Lichtman EI, Seldin DC, Shelton A, Sanchorawala V. Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. <i>Am J Hematol</i>. 2014;89(7):706-708. doi:10.1002/ajh.23722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24668858/pubmed" id="24668858" target="_blank">24668858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24150217">
<a name="24150217"></a>List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. <i>Leukemia</i>. 2014;28(5):1033-1040. doi:10.1038/leu.2013.305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24150217/pubmed" id="24150217" target="_blank">24150217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17021321">
<a name="17021321"></a>List A, Dewald G, Bennett J, et al. Lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. <i>N Engl J Med.</i> 2006;355(14):1456-1465. doi:10.1056/NEJMoa061292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17021321/pubmed" id="17021321" target="_blank">17021321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15703420">
<a name="15703420"></a>List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. <i>N Engl J Med.</i> 2005, 352(6):549-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/15703420/pubmed" id="15703420" target="_blank">15703420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33439748">
<a name="33439748"></a>List AF, Sun Z, Verma A, et al. Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin. <i>J Clin Oncol</i>. 2021;39(9):1001-1009. doi:10.1200/JCO.20.01691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/33439748/pubmed" id="33439748" target="_blank">33439748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26035255">
<a name="26035255"></a>Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. <i>N Engl J Med</i>. 2015;373(7):621-631. doi:10.1056/NEJMoa1505654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26035255/pubmed" id="26035255" target="_blank">26035255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31652094">
<a name="31652094"></a>Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. <i>J Clin Oncol</i>. 2020;38(11):1126‐1137. doi:10.1200/JCO.19.01740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31652094/pubmed" id="31652094" target="_blank">31652094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22571201">
<a name="22571201"></a>McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. <i>N Engl J Med.</i> 2012, 366(19):1770-81. doi:10.1056/NEJMoa1114083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22571201/pubmed" id="22571201" target="_blank">22571201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932732">
<a name="30932732"></a>Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. <i>J Clin Oncol.</i> 2019;37(14):1228-1263. doi:10.1200/JCO.18.02096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/30932732/pubmed" id="30932732" target="_blank">30932732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30190454">
<a name="30190454"></a>Mikhael J, Manola J, Dueck AC, et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. <i>Blood Cancer J.</i> 2018;8(9):86. doi:10.1038/s41408-018-0110-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/30190454/pubmed" id="30190454" target="_blank">30190454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20724537">
<a name="20724537"></a>Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood.</i> 2010;116(23):4777-4782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20724537/pubmed" id="20724537" target="_blank">20724537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23113590">
<a name="23113590"></a>Musolino C, Alonci A, Catena S, et al. Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy. <i>Acta Oncol</i>. 2013;52(5):1050-1051. doi:10.3109/0284186X.2012.732706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23113590/pubmed" id="23113590" target="_blank">23113590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27864218">
<a name="27864218"></a>Musto P, Anderson KC, Attal M, et al; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Ann Oncol</i>. 2017;28(2):228-245. doi:10.1093/annonc/mdw606. Erratum in: <i>Ann Oncol</i>. 2017 May 24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27864218/pubmed" id="27864218" target="_blank">27864218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nice.2014">
<a name="Nice.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. Clnical guideline. Published September 3, 2014. https://www.nice.org/uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22993370">
<a name="22993370"></a>Nojkov B, Signori C, Konda A, Fontana RJ. Lenalidomide-associated hepatotoxicity--a case report and literature review. <i>Anticancer Res</i>. 2012;32(9):4117-4119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22993370/pubmed" id="22993370" target="_blank">22993370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29740809">
<a name="29740809"></a>O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>Br J Haematol</i>. 2018;182(2):222-230. doi:10.1111/bjh.15261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/29740809/pubmed" id="29740809" target="_blank">29740809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22341857">
<a name="22341857"></a>Oehrlein K, Langer C, Sturm I, et al. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. <i>Clin Lymphoma Myeloma Leuk.</i> 2012;12(3):191-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22341857/pubmed" id="22341857" target="_blank">22341857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34027556">
<a name="34027556"></a>Osada SI, Sato T. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms caused by lenalidomide: case report and review of the literature. <i>Acta Derm Venereol</i>. 2021;101(5):adv00468. doi:10.2340/00015555-3835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/34027556/pubmed" id="34027556" target="_blank">34027556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2<sup>nd</sup>, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20048187">
<a name="20048187"></a>Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. <i>J Clin Oncol.</i> 2010;28(5):800-807.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20048187/pubmed" id="20048187" target="_blank">20048187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22571200">
<a name="22571200"></a>Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. <i>N Engl J Med.</i> 2012;366(19):1759-1769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22571200/pubmed" id="22571200" target="_blank">22571200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18094721">
<a name="18094721"></a>Palumbo A, Rajkumar SV, Dimopoulos MA, et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. <i>Leukemia</i>. 2008;22(2):414-423. doi:10.1038/sj.leu.2405062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18094721/pubmed" id="18094721" target="_blank">18094721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22150117">
<a name="22150117"></a>Penna G, Allegra A, Romeo G, et al. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. <i>Acta Oncol</i>. 2012;51(7):944-947. doi:10.3109/0284186X.2011.640347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22150117/pubmed" id="22150117" target="_blank">22150117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16118317">
<a name="16118317"></a>Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. <i>Blood. </i>2005;106(13):4050-4053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/16118317/pubmed" id="16118317" target="_blank">16118317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19853510">
<a name="19853510"></a>Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. <i>Lancet Oncol</i>. 2010;11(1):29-37. doi:10.1016/S1470-2045(09)70284-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/19853510/pubmed" id="19853510" target="_blank">19853510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17893227">
<a name="17893227"></a>Raza A, Reeves JA, Feldman JA, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. <i>Blood.</i> 2008;111(1):86-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17893227/pubmed" id="17893227" target="_blank">17893227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bristol.1">
<a name="Bristol.1"></a>Revlimid (lenalidomide) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Celgene.1">
<a name="Celgene.1"></a>Revlimid (lenalidomide) [product monograph]. Saint-Laurent, Quebec, Canada: Celgene Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12384400">
<a name="12384400"></a>Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood.</i> 2002;100(9):3063-3067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/12384400/pubmed" id="12384400" target="_blank">12384400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385792">
<a name="20385792"></a>Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i>, 2010;116(5):679-686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20385792/pubmed" id="20385792" target="_blank">20385792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429336">
<a name="24429336"></a>Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i>. 2014;123(10):1461-1469. doi:10.1182/blood-2013-07-517276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24429336/pubmed" id="24429336" target="_blank">24429336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31484647">
<a name="31484647"></a>Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. <i>Blood</i>. 2019;134(16):1337-1345. doi:10.1182/blood.2019000241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/31484647/pubmed" id="31484647" target="_blank">31484647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25024076">
<a name="25024076"></a>Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. <i>J Clin Oncol</i>. 2014;32(25):2712-2717. doi:10.1200/JCO.2013.54.8164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/25024076/pubmed" id="25024076" target="_blank">25024076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26535512">
<a name="26535512"></a>Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. <i>N Engl J Med</i>. 2015;373(19):1835-1844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26535512/pubmed" id="26535512" target="_blank">26535512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511983">
<a name="32511983"></a>Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncol</i>. 2020;21(7):978-988. doi:10.1016/S1470-2045(20)30225-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32511983/pubmed" id="32511983" target="_blank">32511983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20847211">
<a name="20847211"></a>Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. <i>Blood. </i>2010;116(11):1990-1991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20847211/pubmed" id="20847211" target="_blank">20847211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16960148">
<a name="16960148"></a>Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. <i>Blood. </i>2007;109(2):492-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/16960148/pubmed" id="16960148" target="_blank">16960148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27354480">
<a name="27354480"></a>Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. <i>J Clin Oncol</i>. 2016;34(25):2988-2996. doi:10.1200/JCO.2015.66.0118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27354480/pubmed" id="27354480" target="_blank">27354480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28874903">
<a name="28874903"></a>Seki JT, Sakurai N, Lam W, Reece DE. Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents. <i>Curr Oncol</i>. 2017;24(4):e328-e332. doi:10.3747/co.24.3572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/28874903/pubmed" id="28874903" target="_blank">28874903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23999760">
<a name="23999760"></a>Shaaban H, Layne T, Guron G. A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. <i>J Oncol Pharm Pract</i>. 2014;20(4):302-304. doi:10.1177/1078155213502569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23999760/pubmed" id="23999760" target="_blank">23999760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29276264">
<a name="29276264"></a>Shanbhag A, Pritchard ER, Chatterjee K, Hammond DA. Highly probable drug reaction with eosinophilia and systemic symptoms syndrome associated with lenalidomide. <i>Hosp Pharm</i>. 2017;52(6):408-411. doi:10.1177/0018578717717394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/29276264/pubmed" id="29276264" target="_blank">29276264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29341834">
<a name="29341834"></a>Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>J Clin Oncol</i>. 2018;36(8):728-734. doi:10.1200/JCO.2017.76.5032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/29341834/pubmed" id="29341834" target="_blank">29341834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22562584">
<a name="22562584"></a>Siniscalchi A, Tendas A, Morino L, et al. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. <i>Support Care Cancer</i>. 2012;20(7):1585-1587. doi:10.1007/s00520-012-1481-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22562584/pubmed" id="22562584" target="_blank">22562584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20693160">
<a name="20693160"></a>Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. <i>Nephrol Dial Transplant</i>. 2011;26(3):881-886. doi:10.1093/ndt/gfq482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20693160/pubmed" id="20693160" target="_blank">20693160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25482145">
<a name="25482145"></a>Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>N Engl J Med</i>. 2015;372(2):142-152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/25482145/pubmed" id="25482145" target="_blank">25482145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810633">
<a name="23810633"></a>Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. <i>Blood</i>. 2013;122(5):734-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23810633/pubmed" id="23810633" target="_blank">23810633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17043184">
<a name="17043184"></a>Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. <i>Arch Dermatol</i>. 2006;142(10):1298-1302. doi:10.1001/archderm.142.10.1298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17043184/pubmed" id="17043184" target="_blank">17043184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16146335">
<a name="16146335"></a>Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. <i>AAPSJ. </i>2005;7(1):e14-e19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/16146335/pubmed" id="16146335" target="_blank">16146335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24387621">
<a name="24387621"></a>Uchiyama A, Motegi S, Yamada K, Uehara A, Ishikawa O. Case of angioedema and urticaria induced by lenalidomide. <i>J Dermatol</i>. 2014;41(2):179-181. doi:10.1111/1346-8138.12379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24387621/pubmed" id="24387621" target="_blank">24387621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32325490">
<a name="32325490"></a>Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i>. 2020;136(8):936-945. doi:10.1182/blood.2020005288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/32325490/pubmed" id="32325490" target="_blank">32325490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22677155">
<a name="22677155"></a>Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncol.</i> 2012;13(7):716-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22677155/pubmed" id="22677155" target="_blank">22677155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21494796">
<a name="21494796"></a>Wäsch R, Jakob T, Technau K, Finke J, Engelhardt M. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation. Ann Hematol. 2012;91(2):287-289. doi:10.1007/s00277-011-1235-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21494796/pubmed" id="21494796" target="_blank">21494796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18032763">
<a name="18032763"></a>Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. <i>N Engl J Med.</i> 2007;357(21):2133-2142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18032763/pubmed" id="18032763" target="_blank">18032763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18606983">
<a name="18606983"></a>Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. <i>J Clin Oncol.</i> 2008;26(30):4952-4967.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18606983/pubmed" id="18606983" target="_blank">18606983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28423741">
<a name="28423741"></a>Ying L, YinHui T, Yunliang Z, Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. <i>Oncotarget</i>. 2017;8(28):46593-46600. doi:10.18632/oncotarget.16235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/28423741/pubmed" id="28423741" target="_blank">28423741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24030098">
<a name="24030098"></a>Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. <i>Ann Oncol</i>. 2013;24(11):2892-2897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24030098/pubmed" id="24030098" target="_blank">24030098</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9822 Version 401.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
